Atkins MB - Search Results

1

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Panka DJ, et al. Among authors: atkins mb. Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15. Mol Cancer Ther. 2014. PMID: 25319388 Free PMC article.

2

Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.

Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ, Kappler K, Mier JW. Atkins MB, et al. J Clin Oncol. 1992 Nov;10(11):1802-9. doi: 10.1200/JCO.1992.10.11.1802. J Clin Oncol. 1992. PMID: 1403061 Clinical Trial.

3

Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters.

Vogelzang PJ, Bloom SM, Mier JW, Atkins MB. Vogelzang PJ, et al. Among authors: atkins mb. Chest. 1992 Mar;101(3):746-52. doi: 10.1378/chest.101.3.746. Chest. 1992. PMID: 1541142

4

Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report.

Sauter NP, Atkins MB, Mier JW, Lechan RM. Sauter NP, et al. Among authors: atkins mb. Am J Med. 1992 Apr;92(4):441-4. doi: 10.1016/0002-9343(92)90278-j. Am J Med. 1992. PMID: 1558092

5

Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy.

Massarotti EM, Liu NY, Mier J, Atkins MB. Massarotti EM, et al. Among authors: atkins mb. Am J Med. 1992 Jun;92(6):693-7. doi: 10.1016/0002-9343(92)90789-e. Am J Med. 1992. PMID: 1605152

6

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.

Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB. Demchak PA, et al. Among authors: atkins mb. J Clin Oncol. 1991 Oct;9(10):1821-30. doi: 10.1200/JCO.1991.9.10.1821. J Clin Oncol. 1991. PMID: 1655988

7

Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy.

Bergstrom RW, Atkins MB, Mier JW, Palmer JP. Bergstrom RW, et al. Among authors: atkins mb. J Clin Lab Immunol. 1990 Apr;31(4):189-93. J Clin Lab Immunol. 1990. PMID: 1967063

8

An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy.

Klempner MS, Noring R, Mier JW, Atkins MB. Klempner MS, et al. Among authors: atkins mb. N Engl J Med. 1990 Apr 5;322(14):959-65. doi: 10.1056/NEJM199004053221404. N Engl J Med. 1990. PMID: 2156163 Free article.

9

Melanotropin receptors demonstrated in situ in human melanoma.

Tatro JB, Atkins M, Mier JW, Hardarson S, Wolfe H, Smith T, Entwistle ML, Reichlin S. Tatro JB, et al. J Clin Invest. 1990 Jun;85(6):1825-32. doi: 10.1172/JCI114642. J Clin Invest. 1990. PMID: 2347915 Free PMC article.

10

Lymphokine-activated killer cell generation and recovery. Comparison of an automated cell processing device and a manual procedure.

Ryan T, Atkins MB, Mier JW, Berkman EM. Ryan T, et al. Among authors: atkins mb. Transfusion. 1989 Jul-Aug;29(6):491-5. doi: 10.1046/j.1537-2995.1989.29689318445.x. Transfusion. 1989. PMID: 2787549

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

478 results

Search Page

Filters